Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

BACKGROUND: Adjuvant trastuzumab improves survival for women with human epidermal growth factor receptor 2‐positive breast cancer, but increases risk for heart failure (HF) and cardiomyopathy (CM). However, clinical trials may underestimate HF/CM risk because they enroll younger subjects with fewer...

Full description

Saved in:
Bibliographic Details
Main Authors: Ezaz, Ghideon, Long, Jessica B., Gross, Cary P., Chen, Jersey
Format: Artigo
Language:Inglês
Published: Blackwell Publishing Ltd 2014
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3959671/
https://ncbi.nlm.nih.gov/pubmed/24584736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.113.000472
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items